Analysts See 14% Gains Ahead For The Holdings of IHI
ETF Analyst Target Prices: The iShares U.S. Medical Devices ETF (IHI) has an implied analyst target price of $69.31, indicating a potential upside of 13.84% from its current trading price of $60.88. Notable underlying holdings with significant upside include Enovis Corp, Treace Medical Concepts Inc, and LivaNova PLC.
Investor Considerations: Analysts' target prices may reflect optimism about future stock performance, but investors should conduct further research to determine if these targets are justified or potentially outdated based on recent developments in the industry.
Trade with 70% Backtested Accuracy
Analyst Views on TMCI
About TMCI
About the author
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Treace Medical Concepts plans to release its financial results for Q4 and full year 2025 before trading on February 27, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:00 am ET to discuss the financial results, requiring investor registration for dial-in numbers and unique PINs, highlighting the company's focus on investor engagement.
- Market Potential: Treace targets the treatment of bunions and related midfoot deformities, with approximately 67 million Americans affected and 1.1 million annual surgical candidates, indicating significant market demand and growth potential.
- Technological Innovation: The launch of Treace's Lapiplasty®3D Bunion Correction System and other related technologies aims to address the root causes of bunions, helping patients return to active lifestyles and enhancing the company's competitive edge in the medical technology sector.
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
Treace Completes First Surgery Using Lapiplasty®Lightning™ Technology
- Technological Innovation: Treace Medical successfully completed the first surgery using its Lapiplasty®Lightning™ technology, which reduces surgical steps and enhances precision, thereby improving surgical efficiency and patient recovery times.
- Market Outlook: The company anticipates initiating a limited market release of the Lapiplasty®Lightning™ System in mid-2026, further driving Treace's market share in foot surgery to meet the growing surgical demand.
- Clinical Feedback: Surgeon William DeCarbo noted that the Lightning technology made the surgical process more intuitive, allowing for three-plane correction without the need for provisional fixation, thus streamlining the surgical workflow and enhancing patient safety.
- Industry Leadership: As a pioneer in 3D bunion correction, Treace solidifies its market leadership through continuous innovation, which is expected to attract more surgeons to adopt its advanced surgical systems.
Treace Medical CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Appearance: Treace Medical's CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am PT, showcasing the company's innovations in foot surgery.
- Investor Relations: Treace encourages investors to regularly visit its website for important information that may impact investment decisions, demonstrating the company's commitment to transparency and investor communication.
- Market Potential: With approximately 67 million Americans affected by bunions, and an estimated 1.1 million surgical candidates annually, Treace's technology is poised to meet significant market demand and drive company growth.
- Technological Innovation: Treace's Lapiplasty®3D Bunion Correction System addresses the root cause of bunions, helping patients return to active lifestyles, reflecting the company's leadership in medical technology.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Johnson Fistel, PLLP Probes Allegations for Long-Term Investors in Quantum Computing Inc. (QUBT), Quanex Building Products Corporation (NX), Treace Medical Concepts, Inc. (TMCI), and BigBear.ai Holdings, Inc. (BBAI)
Investigation of Corporate Governance: Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Quantum Computing Inc., Quanex Building Products Corporation, Treace Medical Concepts, and BigBear.ai Holdings, focusing on corporate governance reforms.
Quantum Computing Inc. Allegations: A securities class action complaint against Quantum Computing alleges misleading statements regarding its technology capabilities, relationships with NASA, and undisclosed related party transactions, which could negatively impact the company's reputation and business.
Quanex Building Products Allegations: The complaint against Quanex claims that the company made false statements about its maintenance practices in Mexico, leading to significant degradation of equipment and potential financial repercussions.
Treace Medical and BigBear.ai Allegations: Treace Medical faces allegations of failing to disclose competitive impacts on its primary product, while BigBear.ai is accused of maintaining deficient accounting practices that led to inaccurate financial statements and potential restatements.
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Treace Medical Concepts plans to release its financial results for Q4 and full year 2025 before trading on February 27, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:00 am ET to discuss the financial results, requiring investor registration for dial-in numbers and unique PINs, highlighting the company's focus on investor engagement.
- Market Potential: Treace targets the treatment of bunions and related midfoot deformities, with approximately 67 million Americans affected and 1.1 million annual surgical candidates, indicating significant market demand and growth potential.
- Technological Innovation: The launch of Treace's Lapiplasty®3D Bunion Correction System and other related technologies aims to address the root causes of bunions, helping patients return to active lifestyles and enhancing the company's competitive edge in the medical technology sector.
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
Treace Completes First Surgery Using Lapiplasty®Lightning™ Technology
- Technological Innovation: Treace Medical successfully completed the first surgery using its Lapiplasty®Lightning™ technology, which reduces surgical steps and enhances precision, thereby improving surgical efficiency and patient recovery times.
- Market Outlook: The company anticipates initiating a limited market release of the Lapiplasty®Lightning™ System in mid-2026, further driving Treace's market share in foot surgery to meet the growing surgical demand.
- Clinical Feedback: Surgeon William DeCarbo noted that the Lightning technology made the surgical process more intuitive, allowing for three-plane correction without the need for provisional fixation, thus streamlining the surgical workflow and enhancing patient safety.
- Industry Leadership: As a pioneer in 3D bunion correction, Treace solidifies its market leadership through continuous innovation, which is expected to attract more surgeons to adopt its advanced surgical systems.
Treace Medical CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Appearance: Treace Medical's CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am PT, showcasing the company's innovations in foot surgery.
- Investor Relations: Treace encourages investors to regularly visit its website for important information that may impact investment decisions, demonstrating the company's commitment to transparency and investor communication.
- Market Potential: With approximately 67 million Americans affected by bunions, and an estimated 1.1 million surgical candidates annually, Treace's technology is poised to meet significant market demand and drive company growth.
- Technological Innovation: Treace's Lapiplasty®3D Bunion Correction System addresses the root cause of bunions, helping patients return to active lifestyles, reflecting the company's leadership in medical technology.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Johnson Fistel, PLLP Probes Allegations for Long-Term Investors in Quantum Computing Inc. (QUBT), Quanex Building Products Corporation (NX), Treace Medical Concepts, Inc. (TMCI), and BigBear.ai Holdings, Inc. (BBAI)
Investigation of Corporate Governance: Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Quantum Computing Inc., Quanex Building Products Corporation, Treace Medical Concepts, and BigBear.ai Holdings, focusing on corporate governance reforms.
Quantum Computing Inc. Allegations: A securities class action complaint against Quantum Computing alleges misleading statements regarding its technology capabilities, relationships with NASA, and undisclosed related party transactions, which could negatively impact the company's reputation and business.
Quanex Building Products Allegations: The complaint against Quanex claims that the company made false statements about its maintenance practices in Mexico, leading to significant degradation of equipment and potential financial repercussions.
Treace Medical and BigBear.ai Allegations: Treace Medical faces allegations of failing to disclose competitive impacts on its primary product, while BigBear.ai is accused of maintaining deficient accounting practices that led to inaccurate financial statements and potential restatements.
